Incomplete Conditional PMA Studies Are Target Of FDA Scrutiny
This article was originally published in The Gray Sheet
Executive SummaryFDA has begun contacting sponsors of approved premarket approval applications with incomplete conditional postmarket studies to assess the status of the investigations.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.